An analyst sees massive upside after the Novo Nordisk deal.

Price change The price of VERU shares has decreased $0.26 since the market last closed. This is a 7.98% drop. Closed at $3.00. The stock has since risen $0.01 in after-hours trading. Veru, Inc. is a ...

Novo Nordisk to support Veru’s Phase 2b PLATEAU trial evaluating enobosarm in combination with Novo Nordisk’s obesity drug Wegovy in older adults receiving Wegovy for weight reduction. Veru will ...

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental ...